Rocco Buccheri

Dr. Rocco Buccheri

Department of Drug and Health Sciences, University of Catania, Catania, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Rocco BuccheriRocco Buccheri
Rocco Buccheri
Antonio RescifinaAntonio Rescifina
Antonio Rescifina
Drug discovery is an intricate and resource-intensive process in which computational approaches, such as molecular docking, are essential, particularly in the early stages, to identify potential hits. However, docking still has many drawbacks, including problems in managing protein flexibility and the reliability of scoring functions. In this paper, we systematically compared the performance of AutoDock Vina, one of the most widely used open-source docking tools, with GNINA. This advanced evolution integrates convolutional neural networks (CNNs) for pose scoring. The comparison was conducted on ten heterogeneous protein targets, including metalloenzymes, kinases, and G-protein-coupled receptors (GPCRs). With the ability to accurately replicate binding poses and their energy values, GNINA showed outstanding performance in both virtual screening (VS) of active ligands and re-docking steps of co-crystallized ligands. GNINA’s enhanced ability to accurately distinguish between true positives and false positives—a specificity not found with AutoDock Vina—is confirmed by ROC curves and Enrichment Factor (EF) results. Therefore, we propose an integrated GNINA-based workflow that can significantly enhance the quality and reliability of docking results, providing a valuable tool for optimizing the initial stages of drug discovery.

Verified
Journal Article
Open access
PDF file
Rocco BuccheriRocco Buccheri
Rocco Buccheri
Alessandro CocoAlessandro Coco
Alessandro Coco
LPLorella Pasquinucci
Lorella Pasquinucci
EAEmanuele Amata
Emanuele Amata
AMAgostino Marrazzo
Agostino Marrazzo
Antonio RescifinaAntonio Rescifina
Antonio Rescifina
Precise binding free-energy predictions for ligands targeting metalloproteins, especially zinc-containing histone deacetylase (HDAC) enzymes, require specialized computational approaches due to the unique interactions at metal-binding sites. This study evaluates a docking algorithm optimized for zinc coordination to determine whether it could accurately differentiate between protonated and deprotonated states of hydroxamic acid ligands, a key functional group in HDAC inhibitors (HDACi). By systematically analyzing both protonation states, we sought to identify which state produces docking poses and binding energy estimates most closely aligned with experimental values. The docking algorithm was applied across HDAC 2, 4, and 8, comparing protonated and deprotonated ligand correlations to experimental data. The results demonstrate that the deprotonated state consistently yielded stronger correlations with experimental data, with R2 values for deprotonated ligands outperforming protonated counterparts in all HDAC targets (average R2 = 0.80 compared to the protonated form where R2 = 0.67). These findings emphasize the significance of proper ligand protonation in molecular docking studies of zinc-binding enzymes, particularly HDACs, and suggest that deprotonation enhances predictive accuracy. The study’s methodology provides a robust foundation for improved virtual screening protocols to evaluate large ligand libraries efficiently. This approach supports the streamlined discovery of high-affinity, zinc-binding HDACi, advancing therapeutic exploration of metalloprotein targets. A comprehensive, step-by-step tutorial is provided to facilitate a thorough understanding of the methodology and enable reproducibility of the results.

Verified
Journal Article
Open access
PDF file
Massimiliano CordaroMassimiliano Cordaro
Massimiliano Cordaro
Giulia NeriGiulia Neri
Giulia Neri
SAShoeb Anwar Ansari
Shoeb Anwar Ansari
Rocco BuccheriRocco Buccheri
Rocco Buccheri
Angela ScalaAngela Scala
Angela Scala
Anna PipernoAnna Piperno
Anna Piperno
This review provides a comprehensive overview of the therapeutic potential of omaveloxone (OMA) for the treatment of Friedreich’s ataxia (FA), along with an analysis of the historical development and current status of the synthetic strategies for OMA production. OMA activates the nuclear factor-2-(erythroid-2)-related (Nrf2) pathway in vitro and in vivo, in both animal models and humans. The Nrf2 pathway plays a crucial role in the cellular response to oxidative stress. Furthermore, OMA has been shown to mitigate mitochondrial dysfunction, restore redox homeostasis and downregulate nuclear factor-κB (NF-κB), a key mediator of inflammatory responses. Through these mechanisms, OMA contributes to tissue protection and inflammation reduction in patients with FA. The review also highlights future perspective, focusing on the challenges associated with OMA reprofiling through innovative drug delivery approaches and its potential repurposing for diseases beyond FA.

Verified
Journal Article
Open access
PDF file
Rocco BuccheriRocco Buccheri
Rocco Buccheri
CRCarlo Reale
Carlo Reale
Alessandro CocoAlessandro Coco
Alessandro Coco
CPCarmela Parenti
Carmela Parenti
LPLorella Pasquinucci
Lorella Pasquinucci
Antonio RescifinaAntonio Rescifina
Antonio Rescifina
δ-opioid receptor (DOR) is a promising therapeutic target for developing safer treatments for pain and neuroprotection. In this study, we applied a structure-guided drug-repurposing workflow to identify FDA-approved drugs with predicted DOR-binding and agonist-like structural features. Using a validated GNINA-based docking protocol with an active-state DOR model (PDB ID: 6PT3), we screened 2342 approved compounds and identified 39 candidates with predicted submicromolar binding affinities. These hits were further evaluated through molecular dynamics simulations, binding pocket volume analysis, and principal component analysis, which enabled the prioritization of two leading candidates, aprepitant and mavorixafor. Both compounds formed stable receptor-ligand complexes, maintained persistent interactions with Asp128, promoted contraction of the orthosteric pocket, and retained favorable redocking scores on the MD-refined receptor conformations. Overall, these results identify aprepitant and mavorixafor as promising putative DOR agonists and provide a rational foundation for their experimental validation through binding, functional, and in vivo pain studies in the future.

Verified
Journal Article
Open access
PDF file
ETElisabetta Grazia Tomarchio
Elisabetta Grazia Tomarchio
Rocco BuccheriRocco Buccheri
Rocco Buccheri
Antonio RescifinaAntonio Rescifina
Antonio Rescifina
Virtual screening (VS) workflows often combine structure- and ligand-based methods; however, their value depends on the number of compounds that can be tested. We benchmarked 20 fixed-budget strategies derived from molecular docking (GNINA CNN score), maximum common substructure (MCS) similarity, and a calibrated machine-learning (ML)-QSAR classifier across five pharmacologically diverse targets. Individual methods, best-rank and worst-rank fusion, mean-rank consensus, and sequential funnels were evaluated at 1%, 5%, and 10% library fractions, with every strategy selecting the same number of compounds. ML-QSAR was the strongest standalone method, recovering 47.6%, 81.6%, and 84.4% of actives at the three cutoffs. At the 1% budget, ML-QSAR achieved the highest mean hit recovery (47.6% recall; 99.2% precision). At 5% and 10%, best-rank fusion of QSAR and MCS produced the highest mean recall (83.2% and 86.4%). Among the sequential workflows, QSAR → MCS achieved the highest 1% hit recovery (45.2 ± 3.3% recall), whereas docking-first funnels consistently underperformed under the default, non-optimized conditions evaluated in this study. Target-level results showed substantial variability in MCS-containing workflows and limited benefits from adding docking without target-specific optimization. Under matched assay budgets, a validated ligand-based predictor or a simple two-method rank-fusion scheme provided the highest observed mean hit recovery without requiring elaborate integration.

27 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Rocco BuccheriRocco Buccheri
Rocco Buccheri
ADAlessia Distefano
Alessia Distefano
CZChiara Zagni
Chiara Zagni
GGGiuseppe Grasso
Giuseppe Grasso
APAnna Piperno
Anna Piperno
Antonio RescifinaAntonio Rescifina
Antonio Rescifina
Ataxia–Telangiectasia (AT) is a rare disorder characterized by ATM deficiency and mitochondrial dysfunction. Because SIRT3 contributes to mitochondrial homeostasis in ATM-deficient settings, it represents a relevant molecular context for repurposing-oriented target-engagement studies. Here, we present an integrated computational and biophysical workflow designed to identify experimentally tractable SIRT3 binders within a clinically approved chemical space. A curated dataset of 2,342 FDA-approved drugs was screened using hierarchical GNINA-based virtual screening, SAveRUNNER network analysis, triplicate 300 ns molecular dynamics simulations, post-MD redocking, MM/PBSA calculations, and experimental SPR validation. Four compounds were prioritized for further investigation: binimetinib, olaparib, mizolastine, and teniposide. Surface plasmon resonance (SPR) demonstrated direct binding of all four compounds to recombinant SIRT3, with equilibrium dissociation constants in the nano- to submicromolar range. Binimetinib showed the highest apparent affinity (KD = 21.28 ±7 nM), followed by olaparib (84 ±8.1 nM), mizolastine (138 ±11 nM), and teniposide (811.25 ±5.3 nM). Computational analyses supported the compatibility of these ligands with dynamically relaxed SIRT3 binding-site conformations and enabled the efficient prioritization of experimentally validated binders. These results support the value of an integrated in silico/SPR pipeline for identifying SIRT3-binding scaffolds and provide a basis for future enzymatic, isoform-selectivity, and cellular studies in ATM-deficient disease models.